CAS: 149820-74-6; Ethyl (3S)-3-[[4-(4-Carbamimidoylanilino)-4-Oxobutanoyl]Amino]Pent-4-Ynoate
该化合物是一种合成化学化合物,主要用于心血管医学,被归类为二乙/三氯丙酮受体敌体,主要用于心血管医学,旨在抑制小板聚积,从而减少急性冠状冠状综合症患者或正在接受腹膜冠状动脉干预的患者中出现血栓形成的风险.该化合物的操作方式是阻塞纤维素和其他粘合分子与血清蛋白IIb/三联分子的结合,这是板块激活和聚积过程中的一个关键步骤. Xemilofiban通常通过静脉注射进行,并研究其临床环境中的功效和安全特征.其致癌基因学涉及迅速分布和消灭,使之适合急性治疗的情景.与许多抗花剂一样,潜在的副作用可能包括血液出血并发症,这需要在治疗期间进行仔细监测.总的来说,Xemlofiban在血管心血管事件管理方面取得重大进展.
- 英文名称Ethyl (3S)-3-[[4-(4-Carbamimidoylanilino)-4-Oxobutanoyl]Amino]Pent-4-Ynoate
- 中文名称珍米洛非班
- IUPAC名称4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, ethyl ester, (S)-
- 其它别名4-Pentynoicacid, 3-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-, ethylester, (S)-; Xemilofiban
- CAS编号149820-74-6
- MFCD编号:MFCD00871094
- FDA UNII编号:P614JI3IYK
- 分子式:C18H22N4O4分子量:358.39
- 产品CID: 723626
- 产品分类有机原料 → 有机酸及其衍生物 → 羧酸及其衍生物
物理性质
MSDS等安全信息
上下游产品
2-Methylpropoxycarbonyl 4-(4-Carbamimidoylanilino)-4-Oxobutanoate 1027293-42-0合成工艺路线路线简述
📜Ethyl (S)-3-Amino-5-(Trimethylsilyl)-4-Pentynoate置于n-甲基吗啉,四丁基氟化铵,氯甲酸异丁酯体系中,化学反应生成珍米洛非班
参考文献:A Very Short,Efficient And Inexpensive Synthesis Of The Prodrug Form Of Sc-54701A A Platelet Aggregation Inhibitor
标题:A Very Short,Efficient And Inexpensive Synthesis Of The Prodrug Form Of Sc-54701A A Platelet Aggregation Inhibitor
摘要:A Short And Efficient Synthesis Of The Prodrug Form Of Sc-54701A Has Been Achieved From (Trimethylsilyl)Acetylene In 6 Steps With An Overall Yield Of 19%. (C) 1997 Elsevier Science Ltd.
Doi:10.1016/s0960-894X(97)00293-X
海关参考信息
- 2901292000-乙炔
2902300000-甲苯
2905121000-正丙醇
2905130000-正丁醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:EP-0912495-B1
优先权日:1996-07-12
标 题 :Asymetric synthesis of chiral beta-amino acids
专利号:CA-2258712-C
优先权日:1996-07-12
标 题 :Asymetric synthesis of chiral beta-amino acids
专利号:US-2014315720-A1
优先权日:2012-10-24
标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
发明人：FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
权利人:CELANESE ACETATE LLC
摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Brugts JJ, Mercado N, Hu S, Guarneri M, Price M, Schatz R, Teirstein P, Wijns W, Serruys PW, O'Neill WW, Boersma E. Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial). Am J Cardiol. 2009 Apr 1;103(7):917-22. doi: 10.1016/j.amjcard.2008.12.017. Epub 2009 Feb 7. doi: 10.1016/j.amjcard.2008.06.035. Epub 2008 Aug 9. Review. Review. Review. Review. Review. Review. Review. Review. Review.
合成参考文献
参考文献:10.1016/s0735-1097(99)00201-6
摘要:Morris DC. Results from late-breaking clinical trials sessions at ACCIS '99 and ACC '99. American College of Cardiology. J Am Coll Cardiol. 1999 Jul;34(1):1–8. doi: 10.1016/s0735-1097(99)00201-6.
参考文献:10.1007/s00018-002-8440-8
摘要:Casserly IP, Topol EJ. Glycoprotein IIb/IIIa antagonists - from bench to practice. Cellular and Molecular Life Sciences (CMLS). 2002 Mar 01;59(3):478–500. doi: 10.1007/s00018-002-8440-8.
参考文献:10.1007/s10016-001-0159-8
摘要:Matsagas MI, Geroulakos G, Mikhailidis DP. The role of platelets in peripheral arterial disease: therapeutic implications. Ann Vasc Surg. 2002 Mar;16(2):246–58. doi: 10.1007/s10016-001-0159-8.
参考文献:10.1186/1471-2350-5-13
摘要:Byrne CE, Fitzgerald A, Cannon CP, Fitzgerald DJ, Shields DC. Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes. BMC Medical Genomics. 2004 Jun 01;5(1):13. doi: 10.1186/1471-2350-5-13.
参考文献:10.1007/bf00735960
摘要:ten Cate H, Nurmohamed MT, ten Cate JW. Developments in antithrombotic therapy: state of the art anno 1996. International Journal of Clinical Pharmacy. 1996 Nov;18(6):195–203. doi: 10.1007/bf00735960.
📝 需求与反馈
尽可能描述清楚需求与问题信息
